| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US214998 | 1980-12-10 | ||
| US21499888A | 1988-07-05 | 1988-07-05 |
| Publication Number | Publication Date |
|---|---|
| EP0378666A1 EP0378666A1 (en) | 1990-07-25 |
| EP0378666A4true EP0378666A4 (en) | 1992-01-22 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19890908361WithdrawnEP0378666A4 (en) | 1988-07-05 | 1989-07-05 | Interleukin ii analogs |
| Country | Link |
|---|---|
| EP (1) | EP0378666A4 (en) |
| JP (1) | JPH03500415A (en) |
| AU (1) | AU627477B2 (en) |
| WO (1) | WO1990000565A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5312903A (en)* | 1990-06-01 | 1994-05-17 | E. I. Du Pont De Nemours And Company | Lysine-glycosylated recombinant interleukin-2 |
| JPH05508634A (en)* | 1990-07-05 | 1993-12-02 | アクゾ・エヌ・ヴエー | Receptor-specific toxin conjugate |
| US6358490B2 (en) | 1992-06-09 | 2002-03-19 | Neorx Corporation | Three-step pretargeting methods and compounds |
| DE69331319T2 (en)* | 1992-06-09 | 2002-08-08 | Neorx Corp., Seattle | Biotin-DOTA conjugates and their use in "pretargeting" processes |
| US5911969A (en) | 1992-06-09 | 1999-06-15 | Neorx Corporation | Pretargeting protocols for enhanced localization of active agents to target sites |
| US5696234A (en)* | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| IL116436A (en) | 1995-12-18 | 2006-12-31 | Yissum Res Dev Co | Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND |
| US6168785B1 (en)* | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| US20060234205A1 (en)* | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| US20110274650A1 (en) | 2009-01-21 | 2011-11-10 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| PL3482766T3 (en)* | 2014-08-11 | 2020-11-16 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| MY188430A (en) | 2015-04-10 | 2021-12-08 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| WO2018089420A1 (en) | 2016-11-08 | 2018-05-17 | Delinia, Inc. | Il-2 variants for the treatment of autoimmune diseases |
| CN115427437B (en) | 2020-03-31 | 2024-04-19 | 韩美药品株式会社 | Novel immunostimulatory IL-2 analogues |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4568640A (en)* | 1981-05-11 | 1986-02-04 | Harvey Rubin | Method of inserting amino acid analogs into proteins |
| EP0108146B1 (en)* | 1982-05-12 | 1987-01-28 | The President And Fellows Of Harvard College | Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof |
| WO1985000817A1 (en)* | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
| US4636463A (en)* | 1984-04-05 | 1987-01-13 | Scripps Clinic And Research Foundation | Antibodies to human interleukin-2 induced by synthetic polypeptides |
| US4761375A (en)* | 1984-05-08 | 1988-08-02 | Genetics Institute, Inc. | Human interleukin-2 cDNA sequence |
| CA1340265C (en)* | 1985-01-18 | 1998-12-15 | Kirston E. Koths | Oxidation resistant muteins |
| US5391485A (en)* | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS62185098A (en)* | 1986-02-10 | 1987-08-13 | Otsuka Pharmaceut Co Ltd | Polypeptide having interleukin ii activity |
| Title |
|---|
| BIOLOGY CHEMISTRY HOPPE-SEYLER, vol. 368, no. 9, 1987, page 1060; R. H\FER et al.: "Modification and introduction of protein glycosylation sites by site-specific mutagenesis: Studies on human interleukin 2"* |
| JOURNAL OF CELLULAR BIOCHEMISTRY-UCLA SYMPOSIA ON MOLECULAR & CELLULAR BIOLOGY, 15th ANNUAL MEETINGS, Suppl. 10A, 20th January-15th February 1986, page 77, abstract no. B32, Alan R. Liss, Inc., New York, US; G. JU et al.: "Site-directed mutagenesis of the human interleukin-2 gene product: Identification of amino acid residues required for biological activity"* |
| See also references ofWO9000565A1* |
| Publication number | Publication date |
|---|---|
| AU627477B2 (en) | 1992-08-27 |
| EP0378666A1 (en) | 1990-07-25 |
| AU3877689A (en) | 1990-02-05 |
| JPH03500415A (en) | 1991-01-31 |
| WO1990000565A1 (en) | 1990-01-25 |
| Publication | Publication Date | Title |
|---|---|---|
| GB8909571D0 (en) | Novel cyclopentano-vitamin d analogs | |
| GB8527729D0 (en) | Airgun | |
| EP0378666A4 (en) | Interleukin ii analogs | |
| AU3335989A (en) | Tyr-peptide analogs | |
| EP0280499A3 (en) | Novel aminohydrocarbyl-substituted ketoximosilanes | |
| ZA882832B (en) | Grf analogs vii | |
| NZ215563A (en) | Interferon composition | |
| IL92508A0 (en) | Novel alpha-cyano-beta-oxopropionamides | |
| EP0190683A3 (en) | Novel aminoalkylpyrdineamides | |
| GB8428653D0 (en) | Diesters | |
| JPS6445371A (en) | Antiviral compound | |
| ZA897150B (en) | Crf analogs | |
| GB2207864B (en) | Antiviral composition comprising isopropyldeoxyuridine | |
| GB8708693D0 (en) | Airguns | |
| PT86544A (en) | Grf analogs iv | |
| JPS6471883A (en) | Antiviral | |
| GB8505486D0 (en) | 1alpha-hydroxyvitamin d2 analogs | |
| GB8615353D0 (en) | Interferon | |
| GB8520048D0 (en) | Airguns | |
| ZA892971B (en) | Tyr-peptide analogs | |
| GB2189713B (en) | Y | |
| GB8620587D0 (en) | Sieves | |
| GR870511B (en) | Peptide analogs | |
| IE891408L (en) | Cyclopentano-vitamin d analogs | |
| ZA882757B (en) | (p-phenoxyphenoxy)-methyl-five-membered hetaryls |
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase | Free format text:ORIGINAL CODE: 0009012 | |
| AK | Designated contracting states | Kind code of ref document:A1 Designated state(s):AT BE CH DE FR GB IT LI LU NL SE | |
| 17P | Request for examination filed | Effective date:19900629 | |
| A4 | Supplementary search report drawn up and despatched | Effective date:19911202 | |
| AK | Designated contracting states | Kind code of ref document:A4 Designated state(s):AT BE CH DE FR GB IT LI LU NL SE | |
| 17Q | First examination report despatched | Effective date:19931020 | |
| STAA | Information on the status of an ep patent application or granted ep patent | Free format text:STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN | |
| 18D | Application deemed to be withdrawn | Effective date:19950201 |